Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05132101
What this trial is testing

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Who this might be right for
Metastatic Breast Cancer
Pfizer 2,758
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Testing effectiveness (Phase 2)Looking for participantsNCT06254690
What this trial is testing

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 102
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Large-scale testing (Phase 3)UnknownNCT03500380
What this trial is testing

RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Who this might be right for
Breast NeoplasmsBreast DiseasesCapecitabine+3 more
RemeGen Co., Ltd. 301
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07767474
What this trial is testing

Evaluate ATX-898 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Antares Therapeutics, Inc 343
Testing effectiveness (Phase 2)WithdrawnNCT05371860
What this trial is testing

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Armando Giuliano
Not applicableLooking for participantsNCT07358182
What this trial is testing

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

Who this might be right for
Trastuzumab-rezetecanHER2-low Breast CancerHER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Testing effectiveness (Phase 2)Ended earlyNCT05583110
What this trial is testing

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
Spanish Breast Cancer Research Group 13
Testing effectiveness (Phase 2)Study completedNCT01973660
What this trial is testing

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 151
Testing effectiveness (Phase 2)Study completedNCT01904903
What this trial is testing

Cardiac Safety Study in Patients With HER2 + Breast Cancer

Who this might be right for
HER2 Positive Breast CancerLeft Ventricular Function Systolic Dysfunction
Medstar Health Research Institute 31
Testing effectiveness (Phase 2)Study completedNCT01432223
What this trial is testing

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

Who this might be right for
Breast CancerHER-2 Positive Breast CancerEffects of Chemotherapy
Osaka Medical College 46
Testing effectiveness (Phase 2)Study completedNCT05659563
What this trial is testing

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

Who this might be right for
Breast CancerBreast Cancer, Early-Onset
MedSIR 92
Testing effectiveness (Phase 2)Ended earlyNCT01729884
What this trial is testing

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
University of Washington 3
Testing effectiveness (Phase 2)Study completedNCT05444998
What this trial is testing

Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer

Who this might be right for
Breast Cancer
Xijing Hospital 20
Large-scale testing (Phase 3)Ended earlyNCT04752332
What this trial is testing

Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 111
Large-scale testing (Phase 3)Not Yet RecruitingNCT07153757
What this trial is testing

De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Fudan University 2,934
Not applicableLooking for participantsNCT06693024
What this trial is testing

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 2,806
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Next Page